Show simple item record

dc.contributor.authorTiu, C
dc.contributor.authorShinde, R
dc.contributor.authorYap, C
dc.contributor.authorRao Baikady, B
dc.contributor.authorBanerji, U
dc.contributor.authorMinchom, AR
dc.contributor.authorde Bono, JS
dc.contributor.authorLopez, JS
dc.date.accessioned2020-07-06T08:52:09Z
dc.date.issued2020-07-01
dc.identifier.citationThe Lancet. Oncology, 2020, 21 (7), pp. 889 - 891
dc.identifier.issn1470-2045
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3801
dc.identifier.eissn1474-5488
dc.identifier.doi10.1016/s1470-2045(20)30339-9
dc.formatPrint
dc.format.extent889 - 891
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectPneumonia, Viral
dc.subjectCoronavirus Infections
dc.subjectNeoplasms
dc.subjectAntiviral Agents
dc.subjectRisk Assessment
dc.subjectClinical Trials, Phase I as Topic
dc.subjectPandemics
dc.subjectUnited Kingdom
dc.subjectBetacoronavirus
dc.subjectData Management
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleA risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.
dc.typeJournal Article
dcterms.dateAccepted2020-05-27
rioxxterms.versionofrecord10.1016/s1470-2045(20)30339-9
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe Lancet. Oncology
pubs.issue7
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume21
pubs.embargo.termsNo embargo
icr.researchteamMedicine (de Bono Prostate)
icr.researchteamClinical Pharmacology – Adaptive Therapy
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamProstate Cancer Targeted Therapy Group
dc.contributor.icrauthorTiu, Crescens
dc.contributor.icrauthorYap, Christina
dc.contributor.icrauthorBanerji, Udai
dc.contributor.icrauthorMinchom, Anna
dc.contributor.icrauthorDe Bono, Johann


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record